- Home
- FONR vs ENTX Comparison
FONR vs ENTX Comparison
Compare FONR & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FONR
- ENTX
- Stock Information
- Founded
- FONR 1978
- ENTX 2010
- Country
- FONR United States
- ENTX Israel
- Employees
- FONR N/A
- ENTX N/A
- Industry
- FONR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FONR Health Care
- ENTX Health Care
- Exchange
- FONR Nasdaq
- ENTX Nasdaq
- Market Cap
- FONR 94.1M
- ENTX 69.6M
- IPO Year
- FONR 1987
- ENTX 2018
- Fundamental
- Price
- FONR $13.78
- ENTX $1.85
- Analyst Decision
- FONR
- ENTX Strong Buy
- Analyst Count
- FONR 0
- ENTX 1
- Target Price
- FONR N/A
- ENTX $10.00
- AVG Volume (30 Days)
- FONR 16.0K
- ENTX 55.8K
- Earning Date
- FONR 02-18-2025
- ENTX 05-09-2025
- Dividend Yield
- FONR N/A
- ENTX N/A
- EPS Growth
- FONR N/A
- ENTX N/A
- EPS
- FONR 1.17
- ENTX N/A
- Revenue
- FONR $101,570,089.00
- ENTX $99,000.00
- Revenue This Year
- FONR N/A
- ENTX N/A
- Revenue Next Year
- FONR N/A
- ENTX N/A
- P/E Ratio
- FONR $11.55
- ENTX N/A
- Revenue Growth
- FONR N/A
- ENTX 607.14
- 52 Week Low
- FONR $13.27
- ENTX $1.30
- 52 Week High
- FONR $22.72
- ENTX $3.35
- Technical
- Relative Strength Index (RSI)
- FONR 36.84
- ENTX 40.63
- Support Level
- FONR $13.27
- ENTX $1.78
- Resistance Level
- FONR $15.12
- ENTX $2.00
- Average True Range (ATR)
- FONR 0.35
- ENTX 0.16
- MACD
- FONR -0.11
- ENTX -0.01
- Stochastic Oscillator
- FONR 27.57
- ENTX 19.44
About FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.